{"id":"NCT01620762","sponsor":"Circassia Limited","briefTitle":"Phase III Cat-PAD Study","officialTitle":"A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2016-06","completion":null,"firstPosted":"2012-06-15","resultsPosted":"2018-05-14","lastUpdate":"2018-06-15"},"enrollment":1408,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rhinoconjunctivitis"],"interventions":[{"type":"DRUG","name":"Cat-PAD","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Cat-Pad Treatment 1","type":"EXPERIMENTAL"},{"label":"Cat-PAD Treatment 2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.","primaryOutcome":{"measure":"Mean Combined Score in Cat-PAD Treatment Groups Compared With Placebo","timeFrame":"52-54 weeks after randomisation","effectByArm":[{"arm":"Cat-PAD Treatment 1 (1 Course)","deltaMin":1.04,"sd":0.068},{"arm":"Cat-PAD Treatment 2 (2 Courses)","deltaMin":1,"sd":0.068},{"arm":"Placebo","deltaMin":1.05,"sd":0.068}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":118,"countries":["United States","Belgium","Canada","Czechia","Germany","Hungary","Poland","Russia","Slovakia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":467},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis","Bronchitis"]}}